-Dr. Warner brings over twenty years of proven
clinical development leadership to TYRA having successfully led
global development and secured approvals for medicines across
oncology and skeletal disease-
CARLSBAD, Calif., Sept. 10,
2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq:
TYRA), a clinical-stage biotechnology company focused on developing
next-generation precision medicines that target large opportunities
in Fibroblast Growth Factor Receptor (FGFR) biology, announced
today the appointment of Doug
Warner, M.D., as Chief Medical Officer. Dr. Warner will be
responsible for overseeing TYRA's clinical portfolio and will serve
as a key member of its executive management team.
"TYRA is at an inflection point with three potentially
best-in-class candidate medicines for oncology and a planned filing
of an IND to support clinical development in achondroplasia later
this year," said Todd Harris, CEO of
TYRA. "Doug has successfully led programs from the earliest stages
of development to securing global registrations in major markets,
and he brings with him significant global development expertise
across both targeted oncology and bone diseases. His background is
a perfect fit for TYRA today, and his proven leadership in guiding
programs to registration will be invaluable as we look to deliver
on the full promise of our precision medicines."
"Joining TYRA as Chief Medical Officer is truly a
compelling opportunity. I am excited to lead a home-grown pipeline
of precision medicines for high-value indications in oncology
and skeletal dysplasias where more effective
treatments are needed," added Dr. Warner. "I look forward to
leading the company's current and future development strategies for
TYRA-300, TYRA-200 and TYRA-430, with the goal of improving
clinical outcomes and people's lives."
Dr. Warner held roles of increasing responsibility over 18 years
at Amgen where he oversaw clinical development for programs across
oncology and bone diseases. This included being an Executive
Director and Group Product Area Lead, where Dr. Warner led a team
responsible for the development of a portfolio of medicines ranging
from those in Phase 1 to those with approved indications, including
Vectibix®, XGEVA®, and Prolia®. Most recently, Dr. Warner was Chief
Medical Officer for eFFECTOR Therapeutics where he was responsible
for overseeing eFFECTOR's clinical pipeline, including its
KICKSTART Phase 2b trial of
tomivosertib in non-small cell lung cancer, and its Phase 1/2 study
of zotatifin in solid tumors. Dr. Warner is co-author of numerous
peer-reviewed articles including those in The Lancet, The Lancet
Oncology, and The Journal of Clinical Oncology. He received his
B.A. from the University of
Pennsylvania, his M.D. from the Duke
University School of Medicine, and his M.B.A. from the UCLA
Anderson School of Management.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage
biotechnology company focused on developing next-generation
precision medicines that target large opportunities in FGFR
biology. The Company's in-house precision medicine platform, SNÅP,
enables rapid and precise drug design through iterative molecular
SNÅPshots that help predict genetic alterations most likely to
cause acquired resistance to existing therapies. TYRA's initial
focus is on applying its accelerated small molecule drug discovery
engine to develop therapies in targeted oncology and genetically
defined conditions. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people,
please visit www.tyra.bio and engage with us on LinkedIn.
Forward-Looking Statements
TYRA cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. The forward-looking statements are
based on our current beliefs and expectations and include, but are
not limited to: the potential to develop next-generation precision
medicines and to have best-in-class candidate medicines for
oncology; the expected timing of a submission of an IND for
achondroplasia; the potential safety and therapeutic benefits of
TYRA-300, TYRA-200, TYRA-430 and other product candidates; and the
potential for SNÅP to develop therapies in targeted oncology and
genetically defined conditions. Actual results may differ from
those set forth in this press release due to the risks and
uncertainties inherent in our business, including, without
limitation: we are early in our development efforts, have only
recently begun testing TYRA-300 and TYRA-200 for oncology in
clinical trials and the approach we are taking to discover and
develop drugs based on our SNÅP platform is novel and unproven and
it may never lead to product candidates that are successful in
clinical development or approved products of commercial value;
potential delays in the commencement, enrollment, data readouts and
completion of preclinical studies and clinical trials; results from
preclinical studies or early clinical trials not necessarily being
predictive of future results; potential difficulty in transitioning
the CMO position and any resulting adverse impacts on our
development programs or otherwise; our dependence on third parties
in connection with manufacturing, research and preclinical testing;
acceptance by the FDA of INDs or of similar regulatory submissions
by comparable foreign regulatory authorities for the conduct of
clinical trials of TYRA-300 in pediatric achondroplasia and
hypochondroplasia; an accelerated development or approval pathway
may not be available for TYRA-300 or other product candidates and
any such pathway may not lead to a faster development process;
later developments with the FDA may be inconsistent with the
minutes from our prior meetings, including with respect to the
proposed design of our planned Phase 2 study of TYRA-300 in ACH;
unexpected adverse side effects or inadequate efficacy of our
product candidates that may limit their development, regulatory
approval, and/or commercialization; the potential for our programs
and prospects to be negatively impacted by developments relating to
our competitors, including the results of studies or regulatory
determinations relating to our competitors; unfavorable results
from preclinical studies; regulatory developments in the United States and foreign countries; and
other risks described in our prior filings with the Securities and
Exchange Commission (SEC), including under the heading "Risk
Factors" in our annual report on Form 10-K and any subsequent
filings with the SEC. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof, and we undertake no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-appoints-doug-warner-md-as-chief-medical-officer-302244061.html
SOURCE Tyra Biosciences